Sony Wibisono (2018) Follow the Leader GLP-1 Agonist Liraglutide Demonstrates Cardioprotective Benefits. In: Proceeding The Quadruple Joint Symposium-2018. Pusat Diabetes dan Nutrisi RSUD Dr. Soetomo, Surabaya, Surabaya, pp. 158-162. ISBN 978-602-71520-9-0

	Text (Artikel) C-34_compressed.pdf Download (993kB)
	Text (Peer Review) C-34 KADEP.pdf Download (2MB)

Abstract

The goals of antidiabetes treatment are to forestall the metabolic effects of high glucose levels and to prevent microvascular and macrovascular complications. Compelling data in type 2 diabetic patients support the conclusion that improved long-termglycemic control reduces the risk of microvascular complications. Based on several large outcome studies (e.g., the Diabetes Control Complications Trial and the UK Prospective Diabetes Study [UKPDS]), glycosylated hemoglobin (HbA1c) was established as a surrogate biomarker of glycemic control and therapeutic goals were set accordingly. Cardiovascular disease is the leading cause of death in patients with type 2 diabetes; more than 60% die of cv disease, and an even greater proportion have serious CV-related complications.

Actions (login required)

View Item